These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 21934621)

  • 1. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
    Popp J; Arlt S
    Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
    Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
    Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms.
    Loi SM; Eratne D; Kelso W; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):358-365. PubMed ID: 29671334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of dementia: anything new?
    Machado JC; Caramelli P
    Curr Opin Psychiatry; 2006 Nov; 19(6):575-80. PubMed ID: 17012934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: early diagnosis and treatment.
    Chu LW
    Hong Kong Med J; 2012 Jun; 18(3):228-37. PubMed ID: 22665688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
    Lachaine J; Beauchemin C; Crochard A; Bineau S
    Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosis in Alzheimer's Disease.
    Ballard C; Kales HC; Lyketsos C; Aarsland D; Creese B; Mills R; Williams H; Sweet RA
    Curr Neurol Neurosci Rep; 2020 Oct; 20(12):57. PubMed ID: 33048274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Review of recommendations and new diagnosis criteria for mild cognitive impairment due to Alzheimer's disease].
    Allegri RF; Russo MJ; Kremer J; Taragano FE; Brusco I; Ollari JA; Serrano CM; Sarasola D; Demey I; Arizaga RL; Bagnati P
    Vertex; 2012; 23(101):5-15. PubMed ID: 22880190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
    Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M
    J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current issues in dementia pharmacotherapy.
    Daiello LA
    Am J Manag Care; 2007 Dec; 13 Suppl 8():S198-202. PubMed ID: 18095783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease.
    Lanari A; Amenta F; Silvestrelli G; Tomassoni D; Parnetti L
    Mech Ageing Dev; 2006 Feb; 127(2):158-65. PubMed ID: 16297434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.